{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:59:44Z","timestamp":1781855984153,"version":"3.54.5"},"reference-count":201,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>An early detection and intervention for dementia represent tremendous unmet clinical needs and priorities in society. A shared feature of neurodegenerative diseases causing dementia is the abnormal accumulation and spreading of pathological protein aggregates, which affect the selective vulnerable circuit in a disease-specific pattern. The advancement in positron emission tomography (PET) biomarkers has accelerated the understanding of the disease mechanism and development of therapeutics for Alzheimer\u2019s disease and Parkinson\u2019s disease. The clinical utility of amyloid-\u03b2 PET and the clinical validity of tau PET as diagnostic biomarker for Alzheimer\u2019s disease continuum have been demonstrated. The inclusion of biomarkers in the diagnostic criteria has introduced a paradigm shift that facilitated the early and differential disease diagnosis and impacted on the clinical management. Application of disease-modifying therapy likely requires screening of patients with molecular evidence of pathological accumulation and monitoring of treatment effect assisted with biomarkers. There is currently still a gap in specific 4-repeat tau imaging probes for 4-repeat tauopathies and \u03b1-synuclein imaging probes for Parkinson\u2019s disease and dementia with Lewy body. In this review, we focused on recent development in molecular imaging biomarkers for assisting the early diagnosis of proteinopathies (i.e., amyloid-\u03b2, tau, and \u03b1-synuclein) in dementia and discussed future perspectives.<\/jats:p>","DOI":"10.3389\/fnagi.2021.751897","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T06:17:30Z","timestamp":1641190650000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia"],"prefix":"10.3389","volume":"13","author":[{"given":"Ruiqing","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Nitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00259-017-3704-6","article-title":"Highlights lecture EANM 2016: \u201cEmbracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine\u201d.","volume":"44","author":"Aboagye","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1093\/brain\/awv278","article-title":"Regional brain hypometabolism is unrelated to regional amyloid plaque burden.","volume":"138","author":"Altmann","year":"2015","journal-title":"Brain"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1007\/s00259-021-05246-x","article-title":"Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison.","volume":"48","author":"Altomare","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2020.01.027","article-title":"Posttranslational modifications mediate the structural diversity of tauopathy strains.","volume":"180","author":"Arakhamia","year":"2020","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41467-021-23157-1","article-title":"Exploring ligand binding pathways on proteins using hypersound-accelerated molecular dynamics.","volume":"12","author":"Araki","year":"2021","journal-title":"Nat. Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","article-title":"Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study.","volume":"141","author":"Attems","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.abj8754","article-title":"Accurate prediction of protein structures and interactions using a three-track neural network.","volume":"373","author":"Baek","year":"2021","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e55031","DOI":"10.1371\/journal.pone.0055031","article-title":"Binding of the radioligand SIL23 to \u03b1-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent.","volume":"8","author":"Bagchi","year":"2013","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","article-title":"Frontotemporal dementia.","volume":"386","author":"Bang","year":"2015","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41582-021-00486-9","article-title":"Prodromal Parkinson disease subtypes \u2013 key to understanding heterogeneity.","volume":"17","author":"Berg","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"B11","author":"Bhatt","year":"2019","journal-title":"The World Alzheimer Report 2019: Attitudes to dementia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41563-019-0332-5","article-title":"Opportunities and challenges using artificial intelligence in ADME\/Tox.","volume":"18","author":"Bhhatarai","year":"2019","journal-title":"Nat. Mater."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s00259-020-05156-4","article-title":"Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework.","volume":"48","author":"Bischof","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes.","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","article-title":"Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy.","volume":"77","author":"Brendel","year":"2020","journal-title":"JAMA Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2967\/jnumed.115.163493","article-title":"Small-animal PET imaging of tau pathology with 18F-THK5117 in 2 transgenic mouse models.","volume":"57","author":"Brendel","year":"2016","journal-title":"J. Nucl. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnagi.2018.00174","article-title":"Comparison of 18F-T807 and 18F-THK5117 PET in a mouse model of tau pathology.","volume":"10","author":"Brendel","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01193-z","article-title":"Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load.","author":"Calsolaro","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"B20","doi-asserted-by":"crossref","first-page":"e043249","DOI":"10.1002\/alz.043249","article-title":"Developing a novel alpha-synuclein positron emission tomography (PET) tracer for the diagnosis of synucleinopathies.","volume":"16","author":"Capotosti","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B21","doi-asserted-by":"publisher","first-page":"eabb8255","DOI":"10.1126\/science.abb8255","article-title":"Tau: enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies.","volume":"371","author":"Chang","year":"2021","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-021-02342-y","article-title":"Comparing amyloid-\u03b2 plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.","volume":"142","author":"Chen","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s00259-018-4040-1","article-title":"Quantitative evaluation of tau PET tracers (18)F-THK5351 and (18)F-AV-1451 in Alzheimer\u2019s disease with standardized uptake value peak-alignment (SUVP) normalization.","volume":"45","author":"Chen","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1016\/j.bmcl.2010.08.016","article-title":"A novel 18F-labeled pyridyl benzofuran derivative for imaging of \u03b2-amyloid plaques in Alzheimer\u2019s brains.","volume":"20","author":"Cheng","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1007\/s00259-021-05301-7","article-title":"Finding our way through the labyrinth of dementia biomarkers.","volume":"48","author":"Ch\u00e9telat","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"B26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","article-title":"Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias.","volume":"19","author":"Ch\u00e9telat","year":"2020","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1007\/s00259-021-05277-4","article-title":"Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework.","volume":"48","author":"Chiotis","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","article-title":"Design, synthesis, and characterization of 3-(Benzylidene)indolin-2-one derivatives as ligands for \u03b1-synuclein fibrils.","volume":"58","author":"Chu","year":"2015","journal-title":"J. Med. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology.","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00259-020-05187-x","article-title":"Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.","volume":"48","author":"Cotta Ramusino","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrd.2017.37","article-title":"Antisense oligonucleotide reverses tau pathology.","volume":"16","author":"Crunkhorn","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.111.094029","article-title":"Clinical validation of 18F-AZD4694, an amyloid-\u03b2-specific PET radioligand.","volume":"53","author":"Cselenyi","year":"2012","journal-title":"J. Nucl. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.","volume":"12","author":"Cullen","year":"2021","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021.","volume":"7","author":"Cummings","year":"","journal-title":"Alzheimers Dement (N Y)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.","volume":"13","author":"Cummings","year":"","journal-title":"Alzheimers Res. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer\u2019s disease.","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2967\/jnumed.116.185199","article-title":"Preclinical evaluation of 18F-JNJ64349311, a novel PET tracer for tau imaging.","volume":"58","author":"Declercq","year":"2017","journal-title":"J. Nucl. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group.","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"B40","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","article-title":"Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease.","volume":"26","author":"Dujardin","year":"2020","journal-title":"Nat. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/mds.27643","article-title":"In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy.","volume":"34","author":"Endo","year":"2019","journal-title":"Mov. Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41583-020-00416-6","article-title":"Reverse engineering Lewy bodies: how far have we come and how far can we go?","volume":"22","author":"Fares","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"12746","DOI":"10.1039\/d0sc02159h","article-title":"Identification of a nanomolar affinity \u03b1-synuclein fibril imaging probe by ultra-high throughput in silico screening.","volume":"11","author":"Ferrie","year":"2020","journal-title":"Chem. Sci."},{"key":"B44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer\u2019s disease.","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes.","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awr038","article-title":"18F-THK523: a novel in vivo tau imaging ligand for Alzheimer\u2019s disease.","volume":"134","author":"Fodero-Tavoletti","year":"2011","journal-title":"Brain"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/brain\/awm177","article-title":"FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer\u2019s disease.","volume":"130","author":"Foster","year":"2007","journal-title":"Brain"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/brain\/awz026","article-title":"Functional connectivity associated with tau levels in ageing, Alzheimer\u2019s, and small vessel disease.","volume":"142","author":"Franzmeier","year":"2019","journal-title":"Brain"},{"key":"B49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers.","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00415-009-5396-8","article-title":"Amyloid PET in mild cognitive impairment and Alzheimer\u2019s disease with BF-227: comparison to FDG\u2013PET.","volume":"257","author":"Furukawa","year":"2009","journal-title":"J. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11307-012-0608-5","article-title":"A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography.","volume":"15","author":"Furumoto","year":"2013","journal-title":"Mol. Imaging Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1255555","DOI":"10.1126\/science.1255555","article-title":"Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein.","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1126\/science.1062097","article-title":"Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils.","volume":"293","author":"Gotz","year":"2001","journal-title":"Science"},{"key":"B54","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/s41380-018-0203-5","article-title":"(18)F-FIBT may expand PET for \u03b2-amyloid imaging in neurodegenerative diseases.","volume":"25","author":"Grimmer","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide.","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum.","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study.","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/brain\/aww098","article-title":"In vivo imaging of neuromelanin in Parkinson\u2019s disease using 18 F-AV-1451 PET.","volume":"139","author":"Hansen","year":"2016","journal-title":"Brain"},{"key":"B59","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/jnen\/nlaa041","article-title":"Biomarkers for neurodegenerative diseases.","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00259-015-3035-4","article-title":"[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer\u2019s disease.","volume":"42","author":"Harada","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B61","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.115.164848","article-title":"18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease.","volume":"57","author":"Harada","year":"2016","journal-title":"J. Nucl. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12149-018-1236-1","article-title":"18F-FPYBF-2, a new F-18-labelled amyloid imaging PET tracer: first experience in 61 volunteers and 55 patients with dementia.","volume":"32","author":"Higashi","year":"2018","journal-title":"Ann. Nucl. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00401-020-02163-5","article-title":"Evidence of distinct \u03b1-synuclein strains underlying disease heterogeneity.","volume":"142","author":"Holec","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","article-title":"Proteopathic tau seeding predicts tauopathy in vivo.","volume":"111","author":"Holmes","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B65","first-page":"L25","article-title":"Translational study of a novel alpha-synuclein PET tracer designed for first-in-human investigating.","volume":"58","author":"Hooshyar Yousefi","year":"2019","journal-title":"Nuklearmedizin"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab289","article-title":"Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms.","author":"Hosokawa","year":"2021","journal-title":"Brain"},{"key":"B67","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.nucmedbio.2011.04.004","article-title":"[18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey.","volume":"38","author":"Hostetler","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","article-title":"Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles.","volume":"57","author":"Hostetler","year":"2016","journal-title":"J. Nucl. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/mds.27623","article-title":"Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features.","volume":"34","author":"Ikeda","year":"2019","journal-title":"Mov. Disord."},{"key":"B70","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00401-020-02175-1","article-title":"Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-\u03b2 plaques in Alzheimer\u2019s disease.","volume":"140","author":"Ikonomovic","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/156720510793611592","article-title":"Tau in Alzheimer disease and related tauopathies.","volume":"7","author":"Iqbal","year":"2010","journal-title":"Curr. Alzheimer. Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies.","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3233\/JAD-170509","article-title":"In vivo visualization of tau accumulation, microglial activation, and brain atrophy in a mouse model of tauopathy rTg4510.","volume":"61","author":"Ishikawa","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00259-013-2620-7","article-title":"Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.","volume":"41","author":"Ito","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B75","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B76","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41593-018-0070-z","article-title":"Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals.","volume":"21","author":"Jacobs","year":"2018","journal-title":"Nat. Neurosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease.","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann. Neurol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases.","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold.","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1021\/acschemneuro.0c00523","article-title":"Identification and evaluation of bisquinoline scaffold as a new candidate for \u03b1-synuclein-PET imaging.","volume":"11","author":"Kaide","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0076-6879(06)12010-8","article-title":"Visualizing pathology deposits in the living brain of patients with Alzheimer\u2019s disease.","volume":"412","author":"Kepe","year":"2006","journal-title":"Methods Enzymol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/brain\/awq091","article-title":"In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy.","volume":"133","author":"Kikuchi","year":"2010","journal-title":"Brain"},{"key":"B83","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40478-019-0840-1","article-title":"Luminescent conjugated oligothiophenes distinguish between \u03b1-synuclein assemblies of Parkinson\u2019s disease and multiple system atrophy.","volume":"7","author":"Klingstedt","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"B84","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B.","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B86","doi-asserted-by":"publisher","first-page":"10598","DOI":"10.1523\/JNEUROSCI.2990-05.2005","article-title":"Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer\u2019s disease brain but not in transgenic mouse brain.","volume":"25","author":"Klunk","year":"2005","journal-title":"J. Neurosci."},{"key":"B87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease.","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"B88","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/mds.27013","article-title":"Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to \u03b1-synuclein pathology.","volume":"32","author":"Koga","year":"2017","journal-title":"Mov. Disord."},{"key":"B89","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1038\/s41467-019-12683-8","article-title":"Cryo-EM structure and polymorphism of A\u03b2 amyloid fibrils purified from Alzheimer\u2019s brain tissue.","volume":"10","author":"Kollmer","year":"2019","journal-title":"Nat. Commun."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","article-title":"Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies.","volume":"46","author":"Kroth","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B91","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1021\/acschemneuro.8b00465","article-title":"Mechanistic Insight into the Binding Profile of DCVJ and \u03b1-synuclein fibril revealed by multiscale simulations.","volume":"10","author":"Kuang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1021\/acschemneuro.9b00578","article-title":"Computational insight into the binding profile of the Second-Generation PET tracer PI2620 with tau fibrils.","volume":"11","author":"Kuang","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2967\/jnumed.106.037556","article-title":"2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer\u2019s disease patients.","volume":"48","author":"Kudo","year":"2007","journal-title":"J. Nucl. Med."},{"key":"B94","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00259-020-05133-x","article-title":"[(11)C]MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates.","volume":"48","author":"Kuebler","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2967\/jnumed.118.214437","article-title":"Evaluation of 18F-RO-948 PET for quantitative assessment of tau accumulation in the human brain.","volume":"59","author":"Kuwabara","year":"2018","journal-title":"J. Nucl. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","article-title":"Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET.","volume":"12","author":"La Joie","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1471-4159.2006.04157.x","article-title":"Monoclonal antibodies that target pathological assemblies of A\u03b2.","volume":"100","author":"Lambert","year":"2007","journal-title":"J. Neurochem."},{"key":"B98","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.dadm.2018.01.007","article-title":"Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding.","volume":"10","author":"Lemoine","year":"2018","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-\u03b2 protein assembly in the brain impairs memory.","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge.","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00259-021-05401-4","article-title":"A multicenter comparison of [(18)F]flortaucipir, [(18)F]RO948, and [(18)F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B102","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","article-title":"Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders.","volume":"77","author":"Leuzy","year":"2020","journal-title":"JAMA Neurol."},{"key":"B103","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2174\/1567205011666141107154201","article-title":"Binding of the PET radiotracer [18F]BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice.","volume":"11","author":"Levigoureux","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/78078","article-title":"Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.","volume":"25","author":"Lewis","year":"2000","journal-title":"Nat. Genet."},{"key":"B105","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/acschemneuro.0c00801","article-title":"Radiosynthesis, in vitro and in vivo evaluation of [(18)F]CBD-2115 as a first-in-class radiotracer for imaging 4R-tauopathies.","volume":"12","author":"Lindberg","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2967\/jnumed.118.208215","article-title":"Brain imaging of Alzheimer dementia patients and elderly controls with (18)F-MK-6240, a PET tracer targeting neurofibrillary tangles.","volume":"60","author":"Lohith","year":"2019","journal-title":"J. Nucl. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2967\/jnumed.119.239418","article-title":"Confirmation of (123)I-FP-CIT SPECT quantification methods in dementia with lewy bodies and other neurodegenerative disorders.","volume":"61","author":"Maltais","year":"2020","journal-title":"J. Nucl. Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.","volume":"78","author":"Marqui\u00e9","year":"2015","journal-title":"Ann. Neurol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"B110","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/cmdc.201900689","article-title":"(11) C radiolabeling of anle253b: a putative PET tracer for Parkinson\u2019s disease that binds to \u03b1-synuclein fibrils in vitro and crosses the blood-brain barrier.","volume":"15","author":"Maurer","year":"2020","journal-title":"ChemMedChem"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262083","article-title":"(11)C-PIB and (124)I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention.","author":"Meier","year":"2021","journal-title":"J. Nucl. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"147131","DOI":"10.1016\/j.brainres.2020.147131","article-title":"Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein.","volume":"1749","author":"Miranda-Azpiazu","year":"2020","journal-title":"Brain Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2967\/jnumed.119.236224","article-title":"Tau PET imaging with (18)F-PI-2620 in patients with Alzheimer\u2019s disease and healthy controls: a first-in-human study.","volume":"61","author":"Mueller","year":"2019","journal-title":"J. Nucl. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00259-019-04305-8","article-title":"Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.","volume":"46","author":"Murugan","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1021\/acs.jpclett.6b01586","article-title":"The culprit is in the cave: the core sites explain the binding profiles of amyloid-specific tracers.","volume":"7","author":"Murugan","year":"2016","journal-title":"J. Phys. Chem. Lett."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/acschemneuro.8b00093","article-title":"Different positron emission tomography tau tracers bind to multiple binding sites on the tau fibril: insight from computational modeling.","volume":"9","author":"Murugan","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1021\/acschemneuro.0c00340","article-title":"Cryptic sites in tau fibrils explain the preferential binding of the AV-1451 PET tracer toward Alzheimer\u2019s tauopathy.","volume":"12","author":"Murugan","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","article-title":"Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.","volume":"50","author":"Nelissen","year":"2009","journal-title":"J. Nucl. Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3390\/ph14111179","article-title":"Positron emission tomography in animal models of Alzheimer\u2019s disease amyloidosis: translational implications.","volume":"14","author":"Ni","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B120","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jalz.2016.08.006","article-title":"Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer\u2019s disease.","volume":"13","author":"Ni","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B121","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2967\/jnumed.117.201632","article-title":"Comparative in-vitro and in-vivo quantifications of pathological tau deposits and their association with neurodegeneration in tauopathy mouse models.","volume":"59","author":"Ni","year":"2018","journal-title":"J. Nucl. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3233\/JAD-201344","article-title":"In vitro characterization of the regional binding distribution of amyloid PET tracer florbetaben and the glia tracers deprenyl and PK1195 in autopsy Alzheimer\u2019s brain tissue.","volume":"80","author":"Ni","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ana.23631","article-title":"Metabolic brain networks in translational neurology: concepts and applications.","volume":"72","author":"Niethammer","year":"2012","journal-title":"Ann. Neurol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00259-009-1182-1","article-title":"Detection of amyloid in Alzheimer\u2019s disease with positron emission tomography using [11C]AZD2184.","volume":"36","author":"Nyberg","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/brain\/awu064","article-title":"Non-invasive assessment of Alzheimer\u2019s disease neurofibrillary pathology using 18F-THK5105 PET.","volume":"137","author":"Okamura","year":"2014","journal-title":"Brain"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","article-title":"Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.","volume":"54","author":"Okamura","year":"2013","journal-title":"J. Nucl. Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"44305","DOI":"10.1039\/C6RA02710E","article-title":"Structure-activity relationships of radioiodinated diphenyl derivatives with different conjugated double bonds as ligands for \u03b1-synuclein aggregates.","volume":"6","author":"Ono","year":"2016","journal-title":"RSC Adv."},{"key":"B128","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/brain\/aww339","article-title":"Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.","volume":"140","author":"Ono","year":"2017","journal-title":"Brain"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.23.349860.","article-title":"In vivo visualization of propagating \u03b1-synuclein pathologies in mouse and marmoset models by a bimodal imaging probe.","author":"Ono","year":"2020","journal-title":"SocArXiv"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity.","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat. Commun."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures.","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat. Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"12263","DOI":"10.1523\/JNEUROSCI.1346-17.2017","article-title":"Multimodal imaging in rat model recapitulates Alzheimer\u2019s disease biomarkers abnormalities.","volume":"37","author":"Parent","year":"2017","journal-title":"J. Neurosci."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41593-020-0686-7","article-title":"Tau induces PSD95-neuronal NOS uncoupling and neurovascular dysfunction independent of neurodegeneration.","volume":"23","author":"Park","year":"2020","journal-title":"Nat. Neurosci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","article-title":"Microglial activation and tau propagate jointly across Braak stages.","volume":"27","author":"Pascoal","year":"2021","journal-title":"Nat. Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","article-title":"18F-MK-6240 PET for early and late detection of neurofibrillary tangles.","volume":"143","author":"Pascoal","year":"2020","journal-title":"Brain"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/mds.27029","article-title":"PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins.","volume":"32","author":"Perez-Soriano","year":"2017","journal-title":"Mov. Disord."},{"key":"B137","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/nrneurol.2014.178","article-title":"Brain connectivity in neurodegenerative diseases\u2013from phenotype to proteinopathy.","volume":"10","author":"Pievani","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/brain\/awm238","article-title":"Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer\u2019s disease.","volume":"130","author":"Pike","year":"2007","journal-title":"Brain"},{"key":"B139","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","article-title":"PET radiotracers: crossing the blood-brain barrier and surviving metabolism.","volume":"30","author":"Pike","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"B140","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.neurobiolaging.2011.12.024","article-title":"PET imaging with [18F]AV-45 in an APP\/PS1-21 murine model of amyloid plaque deposition.","volume":"33","author":"Poisnel","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"B142","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","article-title":"Neuroimaging in Parkinson disease: from research setting to clinical practice.","volume":"10","author":"Politis","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia.","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00259-015-3047-0","article-title":"Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.","volume":"42","author":"Rodriguez-Vieitez","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1021\/acs.jmedchem.8b01759","article-title":"Discovery of N-(4-[18F]fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a new promising tau positron emission tomography imaging tracer.","volume":"62","author":"Rombouts","year":"2019","journal-title":"J. Med. Chem."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2967\/jnumed.112.114660","article-title":"Longitudinal assessment of cerebral \u03b2-amyloid deposition in mice overexpressing Swedish mutant \u03b2-amyloid precursor protein using 18F-florbetaben PET.","volume":"54","author":"Rominger","year":"2013","journal-title":"J. Nucl. Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.112.114785","article-title":"Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for \u03b2-amyloid imaging in aging and dementia.","volume":"54","author":"Rowe","year":"2013","journal-title":"J. Nucl. Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study.","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B150","doi-asserted-by":"publisher","first-page":"12754","DOI":"10.1074\/jbc.RA119.009487","article-title":"Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation.","volume":"294","author":"Saito","year":"2019","journal-title":"J. Biol. Chem."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","article-title":"[(18)F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer\u2019s disease.","volume":"46","author":"Sanabria Boh\u00f3rquez","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias.","volume":"12","author":"Sander","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B153","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.1113694","article-title":"Tau suppression in a neurodegenerative mouse model improves memory function.","volume":"309","author":"SantaCruz","year":"2005","journal-title":"Science"},{"key":"B154","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease.","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"B155","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1007\/s00259-020-04880-1","article-title":"Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer\u2019s disease.","volume":"47","author":"Schmidt","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B156","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrd.2017.232","article-title":"Automating drug discovery.","volume":"17","author":"Schneider","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B157","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1212\/WNL.0b013e31825fdf18","article-title":"Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.","volume":"79","author":"Sch\u00f6ll","year":"2012","journal-title":"Neurology"},{"key":"B158","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ana.25060","article-title":"(18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study.","volume":"82","author":"Schonhaut","year":"2017","journal-title":"Ann. Neurol."},{"key":"B159","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","article-title":"Structures of \u03b1-synuclein filaments from multiple system atrophy.","volume":"585","author":"Schweighauser","year":"2020","journal-title":"Nature"},{"key":"B160","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.1038\/ncomms10759","article-title":"Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer\u2019s disease.","volume":"7","author":"Sehlin","year":"2016","journal-title":"Nat. Commun."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years.","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jamaneurol.2017.0263","article-title":"Hierarchical organization of tau and amyloid deposits in the cerebral cortex.","volume":"74","author":"Sepulcre","year":"2017","journal-title":"JAMA Neurol."},{"key":"B163","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease.","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"B164","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","article-title":"Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy.","volume":"578","author":"Shahnawaz","year":"2020","journal-title":"Nature"},{"key":"B165","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-\u03b2 protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory.","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","article-title":"Structure-based classification of tauopathies.","volume":"598","author":"Shi","year":"","journal-title":"Nature"},{"key":"B167","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00401-021-02294-3","article-title":"Cryo-EM structures of tau filaments from Alzheimer\u2019s disease with PET ligand APN-1607.","volume":"141","author":"Shi","year":"","journal-title":"Acta Neuropathol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s00259-012-2178-9","article-title":"Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer\u2019s disease.","volume":"39","author":"Snellman","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases.","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"B170","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/s1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration.","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.2353\/ajpath.2006.050840","article-title":"Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.","volume":"168","author":"Spires","year":"2006","journal-title":"Am. J. Pathol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.dadm.2018.12.008","article-title":"Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.","volume":"11","author":"Su","year":"2019","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.13817243.v1","article-title":"Structure-guided design, synthesis, and evaluation of 1-indanone and 1,3-indandione derivatives as ligands for misfolded \u03b1-synuclein aggregates.","author":"Sun","year":"2021","journal-title":"ChemRxiv"},{"key":"B174","doi-asserted-by":"publisher","first-page":"35636","DOI":"10.1038\/srep35636","article-title":"Fluselenamyl: a novel benzoselenazole derivative for PET detection of amyloid plaques (A\u03b2) in Alzheimer\u2019s disease.","volume":"6","author":"Sundaram","year":"2016","journal-title":"Sci. Rep."},{"key":"B175","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","article-title":"High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and non-Alzheimer\u2019s disease tauopathies.","volume":"109","author":"Tagai","year":"2020","journal-title":"Neuron"},{"key":"B176","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nbd.2011.05.003","article-title":"[F-18]FDDNP microPET imaging correlates with brain A\u03b2 burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-A\u03b2 antibody treatment.","volume":"43","author":"Teng","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"B177","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","article-title":"[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer\u2019s disease: specific detection of advanced phases of amyloid-\u03b2 pathology.","volume":"11","author":"Thal","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/wnl.58.12.1791","article-title":"Phases of A beta-deposition in the human brain and its relevance for the development of AD.","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"B179","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/molecules25040977","article-title":"PET radiopharmaceuticals for Alzheimer\u2019s disease and Parkinson\u2019s disease diagnosis, the current and future landscape.","volume":"25","author":"Uzuegbunam","year":"2020","journal-title":"Molecules"},{"key":"B180","first-page":"144","article-title":"Optimized disarybisthiazole derivatives with high affinity to alpha-synuclein aggregates and improved pharmacokinetics.","volume":"60","author":"Uzuegbunam","year":"2021","journal-title":"Nuklearmedizin"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.10.451626","article-title":"Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography.","author":"Vagenknecht","year":"2021","journal-title":"bioRxiv"},{"key":"B182","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1021\/acs.molpharmaceut.8b00229","article-title":"In silico, in vitro, and in vivo evaluation of new candidates for \u03b1-synuclein PET imaging.","volume":"15","author":"Verdurand","year":"2018","journal-title":"Mol. Pharm."},{"key":"B183","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","article-title":"Comparison of 11C-PiB and 18F-florbetaben for A\u03b2 imaging in ageing and Alzheimer\u2019s disease.","volume":"39","author":"Villemagne","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B184","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","article-title":"Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease.","volume":"11","author":"Vogel","year":"2020","journal-title":"Nat. Commun."},{"key":"B185","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","article-title":"Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease.","volume":"27","author":"Vogel","year":"2021","journal-title":"Nat. Med."},{"key":"B186","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease.","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1007\/s00259-018-4031-2","article-title":"Clinical utility of FDG PET in Parkinson\u2019s disease and atypical parkinsonism associated with dementia.","volume":"45","author":"Walker","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B188","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1021\/acsmedchemlett.1c00071","article-title":"Characterization and optimization of benzimidazopyrimidine and pyridoimidazopyridine derivatives as Tau-SPECT probes.","volume":"12","author":"Watanabe","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"B189","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","article-title":"Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson\u2019s disease model.","volume":"138","author":"Wegrzynowicz","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamaneurol.2018.0894","article-title":"Use of flutemetamol F 18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive impairment.","volume":"75","author":"Wolk","year":"2018","journal-title":"JAMA Neurol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00259-020-05118-w","article-title":"Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase biomarker development framework.","volume":"48","author":"Wolters","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B192","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40478-018-0535-z","article-title":"Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.","volume":"6","author":"Wren","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"B193","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.1c00062","article-title":"A new highly deuterated [18F]AV-45, [18F]D15FSP, for imaging \u03b2-Amyloid plaques in the brain.","volume":"12","author":"Xiao","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","article-title":"Parkinson\u2019s disease and multiple system atrophy have distinct \u03b1-synuclein seed characteristics.","volume":"294","author":"Yamasaki","year":"2019","journal-title":"J. Biol. Chem."},{"key":"B195","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/brain\/awab120","article-title":"Discriminatory ability of next-generation tau PET tracers for Alzheimer\u2019s disease.","volume":"144","author":"Yap","year":"2021","journal-title":"Brain"},{"key":"B196","first-page":"S22","article-title":"Novel compounds for specific visualization of alpha-synucleinopathies by PET.","volume":"43","author":"Yousefi","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B197","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-015-0090-6","article-title":"FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice.","volume":"5","author":"Yousefi","year":"2015","journal-title":"EJNMMI Res."},{"key":"B198","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/j.bmc.2012.06.023","article-title":"Synthesis and in vitro evaluation of \u03b1-synuclein ligands.","volume":"20","author":"Yu","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"B199","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-020-2043-0","article-title":"Novel tau filament fold in corticobasal degeneration.","volume":"580","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"B200","doi-asserted-by":"publisher","first-page":"739130","DOI":"10.3389\/fimmu.2021.739130","article-title":"PET imaging of neuroinflammation in Alzheimer\u2019s disease.","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1021\/acschemneuro.1c00536","article-title":"Dissecting the binding profile of PET tracers to corticobasal degeneration tau fibrils.","volume":"12","author":"Zhou","year":"2021","journal-title":"ACS Chem. Neurosci."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.751897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T06:17:42Z","timestamp":1641190662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.751897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":201,"alternative-id":["10.3389\/fnagi.2021.751897"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2021.751897","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"article-number":"751897"}}